Abstract：Objective To explore the clinical effect of Dapagliflozin combined with Metformin in the treatment of obese type 2 diabetes mellitus.Methods Ninety-three patients with obese type 2 diabetes mellitus who were treated in our hospital from May 2017 to February 2018 with metformin (2 g/d) alone and whose blood sugar control was still not up to the standard were selected as the study subjects, they were divided into control group (46 cases) and observation group (47 cases) by random number table method.Patients in the control group were treated with Metformin combined with Glimepiride, while patients in the observation group were treated with Metformin combined with Dapagliflozin for 24 weeks.The levels of fasting blood glucose (FBG), postprandial blood glucose (2 h PG), glycosylated hemoglobin(HbA1c), body mass index (BMI), uric acid (UA), hypersensitive C-reactive protein (hs-CRP) and hypoglycemia were compared between the two groups before and after treatment.Results The levels of FBG, 2 h PG, HbA1c and hs-CRP in the two groups after treatment were lower than those before treatment, the differences were statistically significant(P<0.05).After treatment, the level of BMI and hs-CRP in the observation group were lower than those in the control group, the differences were statistically significant (P<0.05).The level of UA in the observation group after treatment was lower than that before treatment and in the control group, the differences were statistically significant (P<0.05).The incidence of hypoglycemia in the observation group was lower than that in the control group, the difference was significant (P<0.05).Conclusion Dapagliflozin combined with Metformin has similar hypoglycemic effect as Glimepiride combined with Metformin, but Dapagliflozin group can significantly reduce weight while lowering blood sugar, and has good safety, anti-inflammatory and hypouric acid effects.
京公网安备 11010502046607号